News & Updates

Show Multimedia Only

Vitamin K homologue menaquinone-7 supplementation may attenuate coronary artery calcification

Supplementation with vitamin K homologue menaquinone-7 (MK-7) for 2 years appears to reduce plaque calcification in patients with symptomatic coronary artery disease, as shown in a study.

Vitamin K homologue menaquinone-7 supplementation may attenuate coronary artery calcification

5 hours ago

Seladelpar improves liver outcomes in cirrhosis patients with PBC, portal hypertension

11 hours ago by

Treatment with seladelpar for 4 years yields consistent biochemical efficacy, with no new safety concerns, among patients with cirrhosis and primary biliary cholangitis (PBC), as shown by interim results from the open-label ASSURE study.

Seladelpar improves liver outcomes in cirrhosis patients with PBC, portal hypertension

11 hours ago

Inhaled treprostinil confers benefit in idiopathic pulmonary fibrosis

a day ago by

Treatment with inhaled treprostinil helps preserve lung function and delay disease progression in patients with idiopathic pulmonary fibrosis (IPF), according to phase 3 data from the TETON-1 trial.

Inhaled treprostinil confers benefit in idiopathic pulmonary fibrosis

a day ago

GLP‐1RA offers cardiovascular, survival benefits in high-risk population

a day ago

The use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) among adults with obesity and concomitant autoimmune diseases appears to lower the incidence of thromboembolic events, emergency department visits, and mortality, according to a study.

GLP‐1RA offers cardiovascular, survival benefits in high-risk population

a day ago

Pemvidutide positively IMPACTs patients with MASH

a day ago by

Treatment with pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 dual receptor agonist, led to significant improvements in primary noninvasive tests (NITs), such as Enhanced Liver Fibrosis (ELF) and Liver Stiffness Measurement (LSM), and weight loss in patients with metabolic dysfunction-associated steatohepatitis (MASH), according to the phase IIb IMPACT trial presented at EASL 2026.

Pemvidutide positively IMPACTs patients with MASH

a day ago

Vemircopan for generalized myasthenia gravis misses mark in phase 2 study

19 Jun 2026

The oral, selective factor D inhibitor vemircopan has shown no evidence of benefit in the treatment of adult patients with acetylcholine receptor antibody-positive (AChR-Ab+) generalized myasthenia gravis in a phase 2 trial.

Vemircopan for generalized myasthenia gravis misses mark in phase 2 study

19 Jun 2026

Is spironolactone combined with low-dose minoxidil safe for hair loss in women?

19 Jun 2026

Combination therapy with oral spironolactone and low-dose oral minoxidil appears safe and tolerable among adult females with hair loss, reports a study. However, those using one or more blood pressure (BP)-altering medications are at increased risk of hypotension-related symptoms.

Is spironolactone combined with low-dose minoxidil safe for hair loss in women?

19 Jun 2026

Orforglipron superior to dapagliflozin in metformin-resistant T2D

19 Jun 2026 by

A recent study comparing dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, with orforglipron, an oral nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist (RA), has found superior glycaemic control and weight loss with the latter.

Orforglipron superior to dapagliflozin in metformin-resistant T2D

19 Jun 2026

Mazdutide cuts weight in adults with obesity, T2D

19 Jun 2026 by

The use of mazdutide among adults with obesity results in a clinically significant weight reduction and improvements in cardiometabolic risk factors, with an acceptable safety profile, as shown in the phase 3 GLORY-2 trial presented at ADA 2026.

Mazdutide cuts weight in adults with obesity, T2D

19 Jun 2026

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

19 Jun 2026 by

In a post hoc analysis of the phase III MAESTRO-NASH trial presented at ADA 2026, systemic thyroid function remained stable with resmetirom, supporting its extrahepatic safety in individuals with metabolic dysfunction-associated steatohepatitis (MASH).

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

19 Jun 2026

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Vitamin K homologue menaquinone-7 supplementation may attenuate coronary artery calcification

Vitamin K homologue menaquinone-7 supplementation may attenuate coronary artery calcification

Seladelpar improves liver outcomes in cirrhosis patients with PBC, portal hypertension

Seladelpar improves liver outcomes in cirrhosis patients with PBC, portal hypertension

Inhaled treprostinil confers benefit in idiopathic pulmonary fibrosis

Inhaled treprostinil confers benefit in idiopathic pulmonary fibrosis

GLP‐1RA offers cardiovascular, survival benefits in high-risk population

GLP‐1RA offers cardiovascular, survival benefits in high-risk population

Pemvidutide positively IMPACTs patients with MASH

Pemvidutide positively IMPACTs patients with MASH

Vemircopan for generalized myasthenia gravis misses mark in phase 2 study

Vemircopan for generalized myasthenia gravis misses mark in phase 2 study

Is spironolactone combined with low-dose minoxidil safe for hair loss in women?

Is spironolactone combined with low-dose minoxidil safe for hair loss in women?

Orforglipron superior to dapagliflozin in metformin-resistant T2D

Orforglipron superior to dapagliflozin in metformin-resistant T2D

Mazdutide cuts weight in adults with obesity, T2D

Mazdutide cuts weight in adults with obesity, T2D

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

MAESTRO-NASH updates validate extrahepatic safety of resmetirom